Terazosin blockade of nicotine-induced skin flap necrosis in the rat

Richard G. Karlen, Robert H Maisel

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Objective: To examine the ability of terazosin hydrochloride to block the decrease in skin flap survival induced by nicotine. Design: A randomized controlled animal trial. Subjects: Ninety-two male Sprague-Dawley rats were randomized to 1 of 5 groups: double-placebo control (n=15), nicotine opposed by oral placebo (n=26), nicotine opposed by subcutaneous placebo (n=16) nicotine opposed by oral terazosin (n=21) and nicotine opposed by subcutaneous terazosin (n=14). Intervention: All rats received 1 mg of nicotine twice daily via subcutaneous injection except for those in the double-placebo control group, which received Saline injections twice daily, for the 6-week study. The terazosin treatment groups received 1.5 mg of terazosin hydrochloride twice daily either orally or subcutaneously while the rest received a saline solution placebo either orally or subcutaneously for the last 4 weeks of the study. At the end of the fifth week, a 4x10-cm, caudally based, dorsal random-pattern flap was elevated and repositioned. The outcome was measured in percentage area of flap survival. Results: The mean (±SEM) area of flap survival for the double-placebo control group was 79%±2%. Nicotine opposed by oral placebo or subcutaneous placebo produced a significant decrease in survival areas (mean [±SEM] area, 73%±2% and 74%±2%, respectively). Nicotine opposed by oral terazosin produced a mean (±SEM) survival area of 81%±2%, which was significantly better than the nicotine opposed by placebo group and similar to the control group (P=.02). Conclusion: Use of oral terazosin elevated flap survival rates to control levels in nicotine-treated rats.

Original languageEnglish (US)
Pages (from-to)837-840
Number of pages4
JournalArchives of Otolaryngology - Head and Neck Surgery
Volume123
Issue number8
DOIs
StatePublished - Jan 1 1997

Fingerprint

Terazosin
Nicotine
Necrosis
Placebos
Skin
Control Groups

Cite this

Terazosin blockade of nicotine-induced skin flap necrosis in the rat. / Karlen, Richard G.; Maisel, Robert H.

In: Archives of Otolaryngology - Head and Neck Surgery, Vol. 123, No. 8, 01.01.1997, p. 837-840.

Research output: Contribution to journalArticle

Karlen, Richard G. ; Maisel, Robert H. / Terazosin blockade of nicotine-induced skin flap necrosis in the rat. In: Archives of Otolaryngology - Head and Neck Surgery. 1997 ; Vol. 123, No. 8. pp. 837-840.
@article{097cd2ec81204fdda46c8059ef5fb251,
title = "Terazosin blockade of nicotine-induced skin flap necrosis in the rat",
abstract = "Objective: To examine the ability of terazosin hydrochloride to block the decrease in skin flap survival induced by nicotine. Design: A randomized controlled animal trial. Subjects: Ninety-two male Sprague-Dawley rats were randomized to 1 of 5 groups: double-placebo control (n=15), nicotine opposed by oral placebo (n=26), nicotine opposed by subcutaneous placebo (n=16) nicotine opposed by oral terazosin (n=21) and nicotine opposed by subcutaneous terazosin (n=14). Intervention: All rats received 1 mg of nicotine twice daily via subcutaneous injection except for those in the double-placebo control group, which received Saline injections twice daily, for the 6-week study. The terazosin treatment groups received 1.5 mg of terazosin hydrochloride twice daily either orally or subcutaneously while the rest received a saline solution placebo either orally or subcutaneously for the last 4 weeks of the study. At the end of the fifth week, a 4x10-cm, caudally based, dorsal random-pattern flap was elevated and repositioned. The outcome was measured in percentage area of flap survival. Results: The mean (±SEM) area of flap survival for the double-placebo control group was 79{\%}±2{\%}. Nicotine opposed by oral placebo or subcutaneous placebo produced a significant decrease in survival areas (mean [±SEM] area, 73{\%}±2{\%} and 74{\%}±2{\%}, respectively). Nicotine opposed by oral terazosin produced a mean (±SEM) survival area of 81{\%}±2{\%}, which was significantly better than the nicotine opposed by placebo group and similar to the control group (P=.02). Conclusion: Use of oral terazosin elevated flap survival rates to control levels in nicotine-treated rats.",
author = "Karlen, {Richard G.} and Maisel, {Robert H}",
year = "1997",
month = "1",
day = "1",
doi = "10.1001/archotol.1997.01900080069008",
language = "English (US)",
volume = "123",
pages = "837--840",
journal = "JAMA Otolaryngology - Head and Neck Surgery",
issn = "2168-6181",
publisher = "American Medical Association",
number = "8",

}

TY - JOUR

T1 - Terazosin blockade of nicotine-induced skin flap necrosis in the rat

AU - Karlen, Richard G.

AU - Maisel, Robert H

PY - 1997/1/1

Y1 - 1997/1/1

N2 - Objective: To examine the ability of terazosin hydrochloride to block the decrease in skin flap survival induced by nicotine. Design: A randomized controlled animal trial. Subjects: Ninety-two male Sprague-Dawley rats were randomized to 1 of 5 groups: double-placebo control (n=15), nicotine opposed by oral placebo (n=26), nicotine opposed by subcutaneous placebo (n=16) nicotine opposed by oral terazosin (n=21) and nicotine opposed by subcutaneous terazosin (n=14). Intervention: All rats received 1 mg of nicotine twice daily via subcutaneous injection except for those in the double-placebo control group, which received Saline injections twice daily, for the 6-week study. The terazosin treatment groups received 1.5 mg of terazosin hydrochloride twice daily either orally or subcutaneously while the rest received a saline solution placebo either orally or subcutaneously for the last 4 weeks of the study. At the end of the fifth week, a 4x10-cm, caudally based, dorsal random-pattern flap was elevated and repositioned. The outcome was measured in percentage area of flap survival. Results: The mean (±SEM) area of flap survival for the double-placebo control group was 79%±2%. Nicotine opposed by oral placebo or subcutaneous placebo produced a significant decrease in survival areas (mean [±SEM] area, 73%±2% and 74%±2%, respectively). Nicotine opposed by oral terazosin produced a mean (±SEM) survival area of 81%±2%, which was significantly better than the nicotine opposed by placebo group and similar to the control group (P=.02). Conclusion: Use of oral terazosin elevated flap survival rates to control levels in nicotine-treated rats.

AB - Objective: To examine the ability of terazosin hydrochloride to block the decrease in skin flap survival induced by nicotine. Design: A randomized controlled animal trial. Subjects: Ninety-two male Sprague-Dawley rats were randomized to 1 of 5 groups: double-placebo control (n=15), nicotine opposed by oral placebo (n=26), nicotine opposed by subcutaneous placebo (n=16) nicotine opposed by oral terazosin (n=21) and nicotine opposed by subcutaneous terazosin (n=14). Intervention: All rats received 1 mg of nicotine twice daily via subcutaneous injection except for those in the double-placebo control group, which received Saline injections twice daily, for the 6-week study. The terazosin treatment groups received 1.5 mg of terazosin hydrochloride twice daily either orally or subcutaneously while the rest received a saline solution placebo either orally or subcutaneously for the last 4 weeks of the study. At the end of the fifth week, a 4x10-cm, caudally based, dorsal random-pattern flap was elevated and repositioned. The outcome was measured in percentage area of flap survival. Results: The mean (±SEM) area of flap survival for the double-placebo control group was 79%±2%. Nicotine opposed by oral placebo or subcutaneous placebo produced a significant decrease in survival areas (mean [±SEM] area, 73%±2% and 74%±2%, respectively). Nicotine opposed by oral terazosin produced a mean (±SEM) survival area of 81%±2%, which was significantly better than the nicotine opposed by placebo group and similar to the control group (P=.02). Conclusion: Use of oral terazosin elevated flap survival rates to control levels in nicotine-treated rats.

UR - http://www.scopus.com/inward/record.url?scp=0030853370&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030853370&partnerID=8YFLogxK

U2 - 10.1001/archotol.1997.01900080069008

DO - 10.1001/archotol.1997.01900080069008

M3 - Article

VL - 123

SP - 837

EP - 840

JO - JAMA Otolaryngology - Head and Neck Surgery

JF - JAMA Otolaryngology - Head and Neck Surgery

SN - 2168-6181

IS - 8

ER -